This report was presented to the 12th session of the Executive Board, on 9 June 2010. It contains the most recent data on the performance of Operations Unit, including an overview of the HIV/AIDS, malaria and tuberculosis portfolio.

1. OPERATIONS & MARKET DYNAMICS UPDATES 12th Executive Board Geneva, 8-9 June 2010

4. OVERVIEW: Current Legal Agreements

5. ALLOCATION OF FUNDS: HIV/AIDS

6. ALLOCATION OF FUNDS: TB

7. ALLOCATION OF FUNDS: MALARIA

8. ALLOCATION OF FUNDS: TRANSVERSAL

10. TRENDS BY NICHE *Excludes PMTCT diagnostics and OI medicines. Estimated patients treated or number of products provided, 2007-2009

11. TRENDS BY NICHE *As reported to UNITAID through Partner annual reports Monies spent (US$) by partners on medicines and diagnostics, 2007-2009*

12. TRENDS BY NICHE *As reported to UNITAID through CHAI annual reports Prices paid (US$) per patient per year for two leading 2 nd line regimens, 2007-2009* 41% reduction, 2007-2009 43% reduction, 2007-2009

13. TRENDS BY NICHE *As reported to UNITAID through CHAI annual reports Prices paid (US$) per patient per year for a leading paediatric regimen, 2008-2009* 53% reduction, 2008-2009

15. Approved Projects EB10/EB11 TB: 2 HIV: 2 Signed MoUs EB10/EB11 HIV: 2 MoU extensions (2 nd line and Paediatric HIV/AIDS Projects); TB: MDR-TB diagnostics (FIND/GDF/GLI). Pending MoUs 3 MoUs, Combined ceiling of US$ 54,114,575 EB APPROVAL STATUS ESTHERAID Phase 2 15,498,374 MDR-TB Acceleration of Access Initiative : Strategic Revolving Fund 22,232,201 MDR TB Scale-Up Initiative (inclusion of India ) 16,384,000 Total 54,114,575

21. RECIPIENT COUNTRIES INCOME CLASSIFICATION WB Classification 2009 (based on quantities) LI LMI UMI WB 2009 87.2% 9.6% 3.2%

22. INCOME CLASSIFICATION BY NICHE HIV/AIDS Tuberculosis Malaria (based on value) % LI 88 LMI 7 UMI 5 TOTAL % LI 87 LMI 10 UMI 3 TOTAL % LI 94 LMI 6 UMI 0 TOTAL

23. REGIONAL GROUPING RECIPIENT COUNTRIES HIV/AIDS Tuberculosis Malaria (based on quantities) Region % AFR 91.24% AMR 0.35% EMR 0.52% EUR 0.18% SEAR 5.46% WPR 2.25% TOTAL 100.00% Region % AFR 49.43% AMR 0.04% EMR 16.73% EUR 4.47% SEAR 27.81% WPR 1.53% TOTAL 100.00% Region % AFR 88.99% AMR 0.00% EMR 9.97% EUR 0.00% SEAR 0.40% WPR 0.64% TOTAL 100.00%

25. HIV/AIDS Top 5 Recipient Countries, Value (US$) *All countries have a generalized HIV epidemic. 10,792 10,288 3,522 18,906 9,450 DALY rates ('000), 2004 WHO Region Income group Country* US$ % total value AFR LI Uganda 49,057,563 12% AFR LI Zambia 47,699,645 12% AFR LI Nigeria 40,502,211 10% AFR LI Kenya 36,531,323 9% AFR LI Mozambique 24,541,801 6% TOTAL 198,590,564 50%

26. TUBERCULOSIS Top 5 Recipient Countries, Value (US$) *Support for India is for TGF Round 6 and additional support in the MDR-TB was approved by EB 10 and this support will make India the leading recipient. 1144 2042 474 252 652 DALY rates ('000), 2004 WHO Region Income group Country US$ % total value SEAR LI India* 17,342,126 15 EUR LMI Azerbaijan 9,977,861 9 SEAR LI Myanmar 6,317,182 6 AFR LI Kenya 5,571,026 5 SEAR LI Bangladesh 5,182,437 5 TOTAL 39%

27. Top 5 Recipient Countries, Value (US$) MALARIA MALARIA 2,347 5,806 3,148 6,467 6,230 DALY rates ('000), 2004 WHO Region Income group Country US$ % total value AFR LI Nigeria 30,550,000 10 AFR LI Democratic Republic of the Congo 25,850,000 9 EMR LI Sudan 20,778,979 7 AFR LI Guinea 15,740,344 5 AFR LI Ethiopia 13,883,410 5 TOTAL 94,601,102 35